Page 1791 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 103 Overview and Choice of Donor of Hematopoietic Stem Cell Transplantation 1595

12. Oliansky DM, Czuczman M, Fisher RI, et al: The role of cytotoxic 20. Blazar BR, Murphy WJ, Abedi M: Advances in graft-versus-host disease
therapy with hematopoietic stem cell transplantation in the treatment of biology and therapy. Nat Rev Immunol 12(6):443–458, 2012.
diffuse large B cell lymphoma: update of the 2001 evidence-based review. 21. Tomblyn M, Chiller T, Einsele H, et al: Guidelines for preventing infec-
Biol Blood Marrow Transplant 17(1):20–47 e30, 2011. tious complications among hematopoietic cell transplantation recipients:
13. Oliansky DM, Gordon LI, King J, et al: The role of cytotoxic therapy a global perspective. Biol Blood Marrow Transplant 15(10):1143–1238,
with hematopoietic stem cell transplantation in the treatment of follicu- 2009.
lar lymphoma: an evidence-based review. Biol Blood Marrow Transplant 22. Rizzo JD, Curtis RE, Socie G, et al: Solid cancers after allogeneic
16(4):443–468, 2010. hematopoietic cell transplantation. Blood 113(5):1175–1183, 2009.
14. Palumbo A, Anderson K: Multiple myeloma. N Engl J Med 23. Kolb HJ: Graft-versus-leukemia effects of transplantation and donor
364(11):1046–1060, 2011. lymphocytes. Blood 112(12):4371–4383, 2008.
15. Krishnan A, Pasquini MC, Logan B, et al: Autologous haemopoietic 24. Kochenderfer JN, Dudley ME, Carpenter RO, et al: Donor-derived
stem-cell transplantation followed by allogeneic or autologous haemo- CD19-targeted T cells cause regression of malignancy persisting
poietic stem-cell transplantation in patients with multiple myeloma after allogeneic hematopoietic stem cell transplantation. Blood
(BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol 122(25):4129–4139, 2013.
12(13):1195–1203, 2011. 25. Davila ML, Riviere I, Wang X, et al: Efficacy and toxicity management
16. McCarthy PL, Owzar K, Hofmeister CC, et al: Lenalidomide of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.
after stem-cell transplantation for multiple myeloma. N Engl J Med Sci Transl Med 6(224):224ra225, 2014.
366(19):1770–1781, 2012. 26. Maude SL, Frey N, Shaw PA, et al: Chimeric antigen receptor T cells
17. Kumar S, Giralt S, Stadtmauer EA, et al: Mobilization in myeloma for sustained remissions in leukemia. N Engl J Med 371(16):1507–1517,
revisited: IMWG consensus perspectives on stem cell collection follow- 2014.
ing initial therapy with thalidomide-, lenalidomide-, or bortezomib- 27. Rooney CM, Leen AM, Vera JF, et al: T lymphocytes targeting native
containing regimens. Blood 114(9):1729–1735, 2009. receptors. Immunol Rev 257(1):39–55, 2014.
18. Anasetti C, Logan BR, Lee SJ, et al: Peripheral-blood stem cells versus 28. Rosenblatt J, Avivi I, Vasir B, et al: Vaccination with dendritic cell/tumor
bone marrow from unrelated donors. N Engl J Med 367(16):1487–1496, fusions following autologous stem cell transplant induces immunologic
2012. and clinical responses in multiple myeloma patients. Clin Cancer Res
19. Majhail NS, Rizzo JD, Lee SJ, et al: Recommended screening and 19(13):3640–3648, 2013.
preventive practices for long-term survivors after hematopoietic cell
transplantation. Biol Blood Marrow Transplant 18(3):348–371, 2012.